Other languages TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Real-time Estimate Cboe BZX Other stock markets 11:04:22 2024-04-26 am EDT			5-day change	1st Jan Change
1.735 ^USD	-3.07%		-10.71%	-50.03%

Apr. 03	TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	CI
Mar. 06	HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	Apr. 03
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	Dec. 20
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	Nov. 20
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	Nov. 20
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	Nov. 10
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	Nov. 10
Top Premarket Gainers	Nov. 10
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
TRACON Pharmaceuticals, Inc. Announces Resignation of Bonne Adams as Chief Operating Officer, Effective October 15, 2023	23-10-06
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned	23-09-18
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial	23-06-20
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10
Sector Update: Health Care Stocks Declining Late Tuesday	23-04-25
Top Midday Decliners	23-04-25
Sector Update: Health Care Stocks Declining Tuesday Afternoon	23-04-25
Sector Update: Health Care	23-04-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Other languages

Filters